ModifiedCignaPolicy IP0182

Spinal Muscular Atrophy - Spinraza

Cigna coverage policy for Spinraza (nusinersen intrathecal injection) detailing prior authorization requirements, clinical criteria for initial and continuation therapy, dosing/regimen and conditions not covered, and applicable billing codes.

Policy Summary

PayerCigna

PolicySpinal Muscular Atrophy - Spinraza

Policy CodePolicy IP0182

Change TypeSelected revisions (08/15/2025) and annual updates

Effective Date

Next Review Date

Key ActionPrior Authorization is required for Spinraza; approvals provided for the stated duration (initial 3 months or single maintenance dose within 4 months) and extended approvals allowed if criteria continue to be met.

SourceLink

POLICY UPDATE CHANGES

Policy title changed from 'Nusinersen' to 'Spinal Muscular Atrophy - Spinraza'; documentation requirements updated throughout the policy.

Initial authorization duration updated from 6 months to 3 months.

Reauthorization duration updated from 12 months to 4 months; added criteria for patients currently receiving Spinraza.

Conditions Not Covered statement updated, including concurrent use with Evrysdi.

Updated genetic testing language from 'Bi-allelic mutation' to 'bi-allelic pathogenic variants'.

Updated documentation requirements throughout the policy.

3Initial authorization duration (months)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.